What Thea Farma spa does

Théa Farma S.p.A. is the Italian operating subsidiary of Laboratoires Théa S.A., a privately held French ophthalmology group controlled by the Chibret family with over 150 years of heritage in eye care. Headquartered in Milan at Via Tiziano 32, the company markets and distributes a specialty pharmaceutical portfolio in Italy covering dry eye disease, glaucoma, ocular allergies, infections, inflammation, mydriasis/anesthesia, corneal lesions, ocular nutrition, and eyelid hygiene. The portfolio spans four product families — prescription drugs, medical devices, nutritional supplements, and lid-care products — and is anchored by proprietary preservative-free drug-delivery platforms including the ABAK® multidose system (a membrane-filtered bottle delivering up to 300 calibrated sterile drops with 3-month post-opening sterility), Steri-Free Technology® gels, EasyGrip® ergonomic delivery, and a dual-active ophthalmic insert for surgical/diagnostic mydriasis.

The company operates a B2B enterprise field-sales motion, selling to hospitals, pharmacies, and individual ophthalmologists and general practitioners through a credential-gated professional network. Pricing is not publicly disclosed and the website restricts product information access to verified medical and pharmacy professionals, consistent with regulated pharmaceutical marketing practice. Therapeutic-area products include the Thealoz® line (trehalose-based preservative-free artificial tears), Hyabak®/Hydrabak® (hyaluronic-acid lubricants), Blephaclean®/Blephasol®/Blephagel®/Blephademodex® (lid hygiene), Blephaeyebag® (warm compress device), Zaspray® (lipid-layer spray), Nutrof Total® and Resvega® (ocular nutrition), and surgical inserts. The positioning is "worldwide leader in preservative-free ophthalmic products," with manufacturing compliance meeting GMP and ISO 9001:2015 standards and products registered in Europe, Japan, and the United States.

Théa Farma is a wholly-owned subsidiary structured as "S.p.A. con unico azionista" (single-shareholder Italian S.p.A.) and reports no independent external investors or public listing. The company extends its commercial footprint through academic and clinical partnerships — including long-standing support for the European Board of Ophthalmology, the European Association for Vision and Eye Research, the University of Auvergne foundation, the Fondation Théa, and a research unit at the Institut de la Vision in Paris — and operates the Théa Academy educational platform for young ophthalmologists launched in Italy in 2023. The TROPHY international clinical case competition and Italian LinkedIn presence round out a professional, regulatorily constrained marketing mix focused on prescriber education rather than direct-to-consumer promotion.

Name

Thea Farma spa

Legal name

THEA Farma spa

Website

https://thea.it

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

101–250 employees

Short description

Théa Farma S.p.A. is the Italian subsidiary of Laboratoires Théa S.A., marketing preservative-free ophthalmic pharmaceuticals, medical devices, supplements, and lid-care products to Italian hospitals, pharmacies, and ophthalmologists through a B2B field-sales motion.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Ophthalmology Pharmaceuticals (HLAIAAAL)

akta.pro secondary industries

Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL), Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

Keywords

• Ophthalmic pharmaceuticals
• Preservative-free eye drops
• Ocular medical devices
• Dry eye treatments
• Eye care supplements

Headquarters

HQ city

Milano

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products: Théa Farma generates revenue through the sale of pharmaceutical drugs, medical devices, supplements, and lid care products for ophthalmology and otorhinolaryngology treatments.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Théa Farma S.p.A. develops, manufactures, and commercializes ophthalmic pharmaceutical products, medical devices, nutritional supplements, and lid-care hygiene products for the Italian market. Its portfolio centers on preservative-free eye drops and specialty ocular therapies distributed to ophthalmologists, hospitals, and pharmacies as part of the Théa Group's European ophthalmology franchise.

Product overview

Théa Farma S.p.A. is an Italian pharmaceutical company specializing in ophthalmology, offering a comprehensive portfolio of eye care products organized into four main categories: prescription medications (Farmaci), medical devices (Dispositivi medici), nutritional supplements (Integratori), and eyelid hygiene products (Lid Care). The company positions itself as a leader in preservative-free ophthalmic formulations, having pioneered the ABAK multidose delivery system in the 1990s. The product portfolio includes artificial tears and lubricants (Thealoz, Hyabak, Hydrabak lines), eyelid hygiene solutions (Blephasol, Blephagel, Blephaclean), warm compress devices (Blephaeyebag), nutritional supplements for eye health (Nutrof Total, Resvega), and advanced drug delivery technologies (ABAK System, Steri-Free Technology, EasyGrip). The company's therapeutic areas cover dry eye disease, glaucoma, ocular allergies, eye infections, inflammation, ocular nutrition, midriasis, corneal lesions, and eyelid hygiene. Théa emphasizes its commitment to preservative-free formulations to protect ocular surface health.

Differentiator

Problem solved

Functional benefit

Brands

• ABAK: A multidose bottle system that delivers preservative-free eye drops, sterile and calibrated for 300 drops
• Steri-Free Technology
• EasyGrip
• Théa Academy
• Blephasol
• Blephagel
• Blephaderm
• Blephaclean
• Blephaeyebag
• Blephademodex
• Hyabak
• Hydrabak
• Thealoz
• Thealoz Total
• Thealoz Gel
• Thealoz DUO
• Zaspray
• Nutrof Total
• Resvega

Products and services

• Preservative-free ophthalmic pharmaceuticals (ABAK® platform)
• Ophthalmic medical devices and inserts
• Ocular nutritional supplements
• Lid-care hygiene products

Quantifiable outcome

• ABAK® bottle provides sterility for up to 3 months after opening vs. 2-4 weeks for preserved bottles
• +1 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core.

• European Board of Ophthalmology (EBO)coreStrategic or Co-development PartnerEBO was founded in London in 1992 with the objective of guaranteeing the highest standards of care in ophthalmology and high-level training through the EBOD diploma in EU countries. Over 600 ophthalmologists from 32 countries participate annually. Théa has supported EBO since its creation.
• European Association for Vision and Eye Research (EVER)coreStrategic or Co-development PartnerEVER is the main research association in ophthalmology in Europe. Théa is a long-standing partner and supporter. The annual congress enables young European researchers to publish their scientific work.
• University of Auvergne (Université d'Auvergne)coreStrategic or Co-development PartnerThéa participated in creating the first university foundation in France established by the University of Auvergne. Financial support enables international projects including researcher exchanges, doctoral scholarships, international partnerships, and young researcher funding.
• Fondation ThéacoreStrategic or Co-development PartnerOne of the two priorities of Théa Foundation is enabling doctors and nurses from French-speaking Africa and Portuguese-speaking regions to train in their own country or in French/international facilities, ensuring local populations benefit from acquired expertise. Théa also collaborated with the University of Auvergne to provide advanced surgical training tools.
• Vision Institute (Institut de la Vision)coreStrategic or Co-development PartnerThéa created a new cooperation mode between public and private research by establishing a research unit within the Vision Institute in Paris, advancing ophthalmic research capabilities.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• AbbVie (Allergan Aesthetics / Eye Care): Allergan's ophthalmology franchise (now part of AbbVie) offers branded ophthalmic products including dry eye (Restasis), glaucoma, and aesthetics-adjacent therapies. A significant broad incumbent competitor in the same therapeutic categories Théa addresses.
• Alcon Inc. Global leader in eye care with a comprehensive portfolio across surgical, vision care, and ophthalmic pharmaceuticals. Alcon competes directly with Théa's pharmaceutical and device offerings and is the dominant incumbent in Italian ophthalmology channels.
• Novartis (Ophthalmology / Xiidra): Pharmaceutical major with an ophthalmology franchise including Xiidra (dry eye) and a broad surgical/retinal portfolio after the Alcon spin-off and subsequent bolt-ons. A globally significant competitor with greater R&D and commercial scale than Théa Farma.
• Roche / Genentech (Lucentis, ophthalmology): Major biopharmaceutical group with a leading retinal ophthalmology franchise (Lucentis, Vabysmo) addressing AMD, DME, and related conditions. Less direct overlap on dry eye/glaucoma but competes for ophthalmology share-of-wallet in Italian specialty channels.
• Bausch + Lomb: Global eye-health division of Bausch Health with broad coverage across ophthalmic pharmaceuticals, contact lenses, and surgical products. Competes with Théa across the Italian prescription and OTC ophthalmology landscape.

Emerging players

• Ocular Therapeutix, Inc. US-based biopharma developing novel ophthalmic therapies including drug-eluting intracanalicular inserts for glaucoma and dry eye. Comparable innovation model focused on advanced ocular drug delivery, overlapping with Théa's insert and preservative-free technologies.
• Nicox S.A. France-based ophthalmology R&D company focused on novel therapeutics for glaucoma, ocular surface, and retinal diseases. Smaller, R&D-centric peer with overlapping therapeutic focus, particularly relevant given both companies' French/Italian ties.

Direct peers

• SIFI S.p.A. Italian-headquartered specialty ophthalmology pharma company developing and marketing therapeutics and medical devices for eye care. SIFI is the closest direct geographic and product peer to Théa Farma, competing across similar Italian ophthalmology channels.
• Santen Pharmaceutical Co., Ltd. Japanese specialty pharmaceutical company fully dedicated to ophthalmology, with a global footprint spanning prescription ophthalmics, dry eye treatments, and surgical devices. Santen is a like-for-like specialty ophthalmology peer in category focus, R&D depth, and preservative-free positioning.

Others

• Laboratoires Théa S.A. (parent): The French parent of Théa Farma, operating the same ophthalmology business globally across EU, Japan, and the US. Material as the parent sets strategy, owns core technologies, and effectively competes with Théa Farma at the group level.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/thea-pharma

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Thea Farma spa